Marco A. Chacon, PhD. has joined Wexford Science & Technology, LLC, as the company’s first Chief Scientific Officer. As a successful serial entrepreneur, Chacon brings a depth of experience that will allow him to help life science companies take full advantage of connections to universities and entrepreneurs that are at the core of Wexford’s Knowledge Communities.
“We are delighted Marco has joined our team and will be bringing his unique talents and expertise to our company” said Jim Berens, founder and CEO of Wexford. “Marco has had great success starting and growing companies at the University of Maryland BioPark and he will be a great asset to our executive management team,” Berens continued.
Chacon may be best known as the Founder and former Chairman of Paragon Bioservices, Inc., a contract development and GMP manufacturing organization (CDMO) that specialized in process development and GMP manufacturing of viral vectors for gene therapy. In May of 2019, Paragon was acquired by Catalent Pharma Solutions—a global CMO—for $1.2 Billion.
Most recently, Chacon was the Founder and President of IRAZÚ Bio-Holdings LLC., a company dedicated to early-stage technology development, while bridging the uncertain divide between academic research and drug development.
“It is with great joy that I start a new chapter in my long career as CSO of Wexford Science & Technology—a visionary organization dedicated to the creation of Knowledge Communities. It is in this capacity that I will continue to engage in one of my life’s passions…to support translational medicine and early-stage technology development while promoting entrepreneurship and the convergence of Academic Research and Industry,” said Marco Chacon.
Dr. Chacon’s academic interests include energy metabolism, oxygen homeostasis and the regenerative potential of tissues and organs.
